Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Subscribe To Our Newsletter & Stay Updated